---
schema_version: "secwatch.filing_event.v1"
accession: "0001638833-26-000074"
form_type: "8-K"
ticker: "SGRY"
cik: "0001638833"
company_name: "Surgery Partners, Inc."
filed_at: "2026-08-10T11:32:04+00:00"
generated_at: "2026-08-10T11:35:25.281476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surgery Partners Q2 revenue up 2.7% to $848.9M; reaffirms FY2026 guidance

## Summary
- Q2 revenue $848.9M, up 2.7% YoY; same-facility revenue +5.0%, cases +0.3%.
- Net loss attributable to SGRY $15.0M; Adjusted EBITDA $125.2M vs $129.0M in Q2 2025.
- FY2026 guidance reaffirmed: revenue $3.35-3.45B, Adjusted EBITDA at least $530M, excluding pending Idaho Falls divestiture.
- Pending Idaho Falls, Idaho facility divestiture subject to physician member and governing board approvals; expected to improve cash conversion and deleverage.
- Cash $216.7M, $617.8M revolver capacity; net debt/EBITDA ~4.4x; Q2 operating cash flow $59.3M vs $81.3M.

## SEC filing metadata
- accession: 0001638833-26-000074
- form_type: 8-K
- ticker: SGRY
- cik: 0001638833
- company_name: Surgery Partners, Inc.
- filed_at: 2026-08-10T11:32:04+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000074/0001638833-26-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000074/sgry-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001638833-26-000074
- JSON: https://secwatch.observer/filing/0001638833-26-000074.json
- Plain text: https://secwatch.observer/filing/0001638833-26-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.